Research progress on PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer / 中国胸心血管外科临床杂志
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
;
(12): 953-959, 2020.
Artículo
en Chino
| WPRIM
| ID: wpr-824998
ABSTRACT
@#Programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) signaling pathway has been found capable of affecting anti-tumor immune effect in many malignancies in recent years. Patients who are diagnosed with advanced non-small cell lung cancer (NSCLC) have considerable responses after receving inhibitors against PD-1/PD-L1. This paper reviews the clinical progress of PD-1/PD-L1 inhibitors in the treatment of NSCLC.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
Año:
2020
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS